A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease

• Type of Material: Article
• Authors: Stephen Klatt, University of Melbourne; James D Doecke, Cooperat Res Ctr Mental Hlth; Anne Roberts, Emory University; Berin A Boughton, University of Melbourne; Colin L Masters, University of Melbourne; Malcolm Horne, University of Melbourne; Blaine Roberts, Emory University
• Language: English
• Date: 2021-10-14
• Publisher: NATURE PORTFOLIO
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2021
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1038/s41531-021-00239-x
• Title of Journal or Parent Work: NPJ PARKINSONS DISEASE
• Volume: 7
• Issue: 1
• Start Page: 94
• End Page: 94
• Keywords: ALLOSTERIC MODULATION; Life Sciences & Biomedicine; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; AMINO-ACIDS; Science & Technology; Neurosciences; Neurosciences & Neurology; SUBSTANTIA-NIGRA; KYNURENINE METABOLISM; NEURODEGENERATIVE DISORDERS; QUINOLINIC ACID; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID
• Research Categories: Chemistry, Biochemistry

Abstract

Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic.